Equity
Total Equity
Vertex Pharmaceuticals Total Equity increased by 3.7% to $19.36B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 17.4%, from $16.50B to $19.36B. Over 5 years (FY 2020 to FY 2025), Total Equity shows an upward trend with a 16.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryLiquidity
SignalHigher is better
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
How to read this metric
Growth in equity generally signals increasing value creation and financial health over time.
Detailed definition
This is the residual interest in the assets of the company after deducting all liabilities. It represents the net book v...
Peer comparison
Used as a benchmark for return on equity (ROE) calculations across the pharmaceutical sector.
Metric ID:
total_stockholders_equityHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.20B | $9.53B | $10.10B | $10.91B | $11.93B | $13.03B | $13.91B | $14.43B | $15.47B | $16.51B | $17.58B | $18.55B | $14.77B | $15.63B | $16.41B | $16.50B | $17.18B | $17.32B | $18.67B | $19.36B |
| QoQ Change | — | +3.6% | +6.0% | +8.0% | +9.4% | +9.2% | +6.8% | +3.7% | +7.2% | +6.7% | +6.5% | +5.5% | -20.3% | +5.8% | +5.0% | +0.5% | +4.1% | +0.8% | +7.8% | +3.7% |
| YoY Change | — | — | — | — | +29.8% | +36.7% | +37.7% | +32.3% | +29.6% | +26.7% | +26.4% | +28.5% | -4.5% | -5.3% | -6.7% | -11.1% | +16.2% | +10.8% | +13.7% | +17.4% |
Range$9.20B – $19.36B
CAGR+17.0%
Avg YoY Growth+17.4%
Median YoY Growth+21.9%
Current Streak7 quarters growth
Total Equity at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's total equity?
- Vertex Pharmaceuticals (VRTX) reported total equity of $19.36B in Q1 2026.
- How has Vertex Pharmaceuticals's total equity changed year-over-year?
- Vertex Pharmaceuticals's total equity increased by 17.4% year-over-year, from $16.50B to $19.36B.
- What is the long-term trend for Vertex Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's total equity has grown at a 16.5% compound annual growth rate (CAGR), from $8.69B to $18.67B.
- What does total equity mean?
- The total value of the company belonging to shareholders after all debts are paid.